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Bone mineral density (BMD) loss is common in survivors of allogeneic hematopoietic cell transplantation
(alloHCT). We performed a multicenter, phase II, randomized open-label trial of intravenous zoledronic acid
(ZA) to prevent BMD loss in adult recipients of alloHCT with osteopenia before HCT. The treatment group
received ZA 4 mg intravenously within 28 days pre-HCT and at 3 and 6 months after HCT. Both treatment and
control groups received calcium carbonate and vitamin D supplements. Of 61 patients, 32 were randomized
to the ZA cohort and 29 to the control cohorts. More patients in the ZA group had an HCT comorbidity index
high-risk score of 3 (50% versus 21%, P < .01). Baseline BMD, T-scores, serum osteocalcin, bone alkaline
phosphatase, and urine N-telopeptide (UNTX) levels were similar in both cohorts. Thirty patients were
evaluable for outcomes (11 from the treatment and 19 from the control group). At 12 months, subjects in the
treatment group had an improvement in BMD at the femoral neck (mean change, .018 for ZA group versus
.054 for controls; P ¼ .04) and a signiﬁcant decline in levels of UNTX (56 for ZA group versus 9 for
control; P ¼ .04) compared with baseline. ZA was well tolerated and not associated with any cases of
osteonecrosis of jaw or renal impairment. Lower survival observed in the ZA cohort was likely related to
baseline imbalance in HCT-CI scores. Intermittent ZA is effective in preserving long-term bone health in adult
alloHCT recipients at risk for osteoporosis.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION have suggested that standard nonpharmacological prophy-
Bone complications, including bone mineral density
(BMD) loss, osteopenia, osteoporosis, and avascular necrosis
of bone, are relatively common complications in long-term
transplantation survivors. Approximately one-half of alloge-
neic hematopoietic cell transplantation (alloHCT) recipients
suffer bone loss after transplantation [1-3]. Pretransplantation
chemotherapy, conditioning regimen toxicity, calcineurin
inhibitors for graft-versus-host disease (GVHD) prophylaxis,
and steroid use for GVHD therapy, as well as various nutri-
tional and endocrine factors, have been implicated in post-
HCT osteoporosis [4,5]. It is also likely that known risk
factors for osteoporosis in the general population, such as
older age, low body mass index, genetic predisposition, and
long immobilization, contribute to bone loss in this setting,
too [5,6]. Some studies have suggested that the majority of
bone loss occurs in the ﬁrst year after HCT with subsequent
variable recovery depending on the presence of concomitant
risk factors [7-9]. The common sites of bone loss after HCTare
the lumbar spine and the femoral neck, which predispose
patients to vertebral compression fractures and femoral neck
fractures [10].
Bisphosphonates are agents that act primarily on osteo-
clasts, inhibiting bone resorption, but they may also stimu-
late osteoblasts to promote bone formation. Prior studiesdgments on page 1366.
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13.06.015laxis measures are inadequate [11,12]. Many uncontrolled
studies have reported the use of different bisphosphonates
in the post-HCT setting to prevent or treat osteoporosis
[2,13-19]. Given the lack of randomized studies or studies
with sufﬁcient patient numbers and the variability in the
number, dosing frequency, and speciﬁc agents used, no
ﬁrm conclusions can be drawn from prior research. Zole-
dronic acid (ZA), a third-generation nitrogen-containing
bisphosphonate, is a highly potent bisphosphonate, which
decreases osteoclast-mediated bone resorption [20]. Zole-
dronic acid, when intravenously administered at relatively
long intervals, can improve bone strength [21]. In the general
population, ZA in once yearly or once every 2 years dosing
has been used for the treatment and prevention of osteo-
porosis, respectively [21,22]. On the other hand, long-term
use of bisphosphonates can lead to a rare but serious
complication known as osteonecrosis of the jaw (ONJ), as
well as renal dysfunction. ONJ has been reported more
frequently after treatment with zoledronic acid for multiple
myeloma or metastatic breast cancer [23-25].
We performed a phase II, randomized, open-label trial of
intravenous ZA to prevent bone mineral loss in adult alloHCT
recipients who had pre-existing osteopenia before HCT.
PATIENTS AND METHODS
Patients
Eligible adult (>18 years old) patients underwent screening evaluation
with a dual-energy x-ray absorptiometry (DEXA) scan before alloHCT.
Patients were eligible regardless of donor source, stem cell type, or intensity
of conditioning regimen. Patients with multiple myeloma, renal dysfunc-
tion, or concomitant active dental or endocrine problems at baseline were
excluded. Consenting patients with baseline pretransplantation osteopeniaTransplantation.
Table 1
Patient Characteristics
Factor Zoledronic
Acid
Standard
of Care
P
Value
No. 33 31
No. excluded (withdrew
consent)
1 2
No. evaluable 32 29
Center .77
MN/WI 21/11 18/11
Karnofsky at baseline .39
100 9 (29%) 6 (22%)
90 14 (45%) 17 (63%)
80 6 (19%) 4 (15%)
70 2 (6%) 0
Disease risk 0.82
Standard risk 25 (58%) 20 (56%) .62
High risk 18 (42%) 16 (44%)
Age, median (range), yr 55 (22 to 69) 51 (28 to 70)
Diagnosis .63
ALL 3 (9%) 5 (17%)
AML 16 (50%) 13 (45%)
CML 2 (6%) 1 (3%)
CLL/SLL 1 (3%) 3 (10%)
MDS 2 (6%) 2 (7%)
NHL 4 (13%) 5 (17%)
Hodgkin’s 2 (6%) 0
CMML 1 (3%) 0
Other malignancy 1 (3%) 0
Donor type .47
Sibling 14 (44%) 12 (41%)
Unrelated donor 4 (3%) 7 (24%)
Cord blood 14 (44%) 10 (34%)
Gender .17
Male 23 (72%) 16 (55%)
Race .73
Caucasian 31 (97%) 28 (97%)
Asian/American Indian 1 (3%) 1 (3%)
Conditioning .83
Myeloablative 13 (41%) 11 (38%)
Nonmyeloablative 19 (59%) 18 (62%)
Comorbidity score <.01
Low risk (0) 12 (38%) 9 (31%)
Intermediate risk (1 to 2) 4 (13%) 14 (48%)
High risk (3) 16 (50%) 6 (21%)
Conditioning regimen
Bu/Cy 2 (6%) 6 (21%)
Bu/Flu 3 (9%) 0
Cy/Flu/TBI 14 (44%) 10 (34%)
Cy/Flu/TBI/ATG 2 (6%) 0
Cy/TBI 6 (19%) 7 (24%)
Cy/TBI/ATG 3 (9%) 1 (3%)
Flu/Cy/Rituxan 1 (3%) 1 (3%)
Flu/TBI 1 (3%) 4 (14%)
GvHD Prophylaxis
CSA/MMF 17 (53%) 12 (41%)
CSA/MTX 1 (3%) 3 (10%)
Sirolimus/MMF/Tac 0 1 (3%)
Sirolimus/MMF 2 (6%) 3 (10%)
Sirolimus/Tac 1 (3%) 0
Tacrolimus 3 (9%) 2 (7%)
Tacrolimus/MTX 8 (25%) 8 (28%)
Year of enrollment .64
2006 4 (13%) 4 (14%)
2007 3 (9%) 4 (14%)
2008 6 (19%) 9 (31%)
2009 14 (44%) 10 (34%)
2010 5 (16%) 2 (7%)
MN indicates Minnesota; WI, Wisconsin; ALL, acute lymphoblastic
leukemia; AML, acute myelogenous leukemia; CML, chronic myeloid
leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous
leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomono-
cytic leukemia; SLL, small lymphocytic leukemia; FLU, ﬂudarabine; BU,
busulfan; Cy, cyclophosphamide; TBI, total body irradiation; ATG, antithy-
mocye globulin; CSA, cyclosporine; MMF, mycophenolate; MTX, metho-
trexate.
Data are presented as n (%) unless otherwise indicated.
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the proximal femur, or both, were enrolled. Subjects were randomly allo-
cated by block randomization stratiﬁed by center and type of conditioning
(myeloablative versus nonmyeloablative) to the treatment or control arms.
Study Treatments
All randomized subjects (treatment and control groups) received
1000 mg of calcium carbonate and 400 IU to 500 IU of vitamin D orally daily.
All study subjects were educated on the beneﬁts of weight-bearing physical
exercise and encouraged to remain active and refrain from tobacco smoking
and alcohol consumption. Subjects randomized to the treatment arm
received ZA 4 mg intravenous infusions (in 100 mL of sterile .9% sodium
chloride, USP, or 5% dextrose, USP, infused over a minimum of 15 minutes;
drug provided by Novartis Pharmaceutical Corporation Basel, Switzerland)
before HCT and at 3 and 6months after HCT. Control subjects did not receive
any additional therapy for bone strength. The study treatment assignment
was not blinded. Institutional review boards at each of the participating
institutions (University of Minnesota and Medical College of Wisconsin)
approved the protocol and all patients gave informed consent.
ZA Dose Modiﬁcations
Serum creatinine and estimated glomerular ﬁltration rate were calcu-
lated before each infusion of ZA. For subjects with creatinine clearance
between 30 mL/min and 59 mL/min, ZA was administered over 30 minutes,
and for those with creatinine clearance <30 mL/min, the dose was deferred.
Bone Densitometry
The primary measurement consisted of baseline BMD measurements,
with follow-up BMD measurements at 12 months. BMD was measured by
DEXA scan at the lumbar spine (L1 to L4 vertebrae) and femoral neck. The
instruments at each study site were calibrated and checked on an ongoing
basis to account for drift or instrument variability. The results were
expressed in g/cm2 of BMD and also as T-score and Z-score. Change in BMD
from baseline to 12 months after enrollment was calculated as the primary
outcome measure.
Markers of Bone Metabolism
Serum osteocalcin, serum bone-speciﬁc alkaline phosphatase (BSAP),
and urinary N telopeptide (UNTX) were measured at baseline and at 6 and
12 months after transplantation for all patients.
Hormone Measurements
Thyroid function (thyroid stimulating hormone [TSH] and free T4), total
testosterone in males, and estradiol, luteinizing hormone (LH), and follicle-
stimulating hormone (FSH) in females were measured at baseline and at
12 months after HCT.
Outcomes
The primary outcome was the change in BMD, as measured at the
femoral neck, from baseline to 12 months after enrollment. A secondary
outcome included the change in BMD, asmeasured at the lumbar spine, from
baseline to 12 months after enrollment. Other secondary outcomes included
differences in bone resorption markers, performance status, creatinine and
calcium levels from baseline to 3, 6, or 12 months after transplantation. To
detect a 3% difference in BMD from baseline with 80% power and a type I
error rate of 5%, our design estimated that 43 patients were needed in each
cohort. Based on this estimate, and accounting for a 1-year mortality of up to
20%, our estimated sample size for the trial was set at 106 patients. The study
was terminated in June 2010 after 61 patients were randomized (39 at the
University of Minnesota and 22 at the Medical College of Wisconsin), as
further accrual was difﬁcult at previous funding levels.
Deﬁnitions and Statistical Methods
Patient, disease, and transplantation characteristics at baseline were
compared across randomization groups. Disease risk at the time of HCT was
classiﬁed into standard risk or high risk based on the American Society for
Blood and Marrow Transplantation request for information 2006 risk
scoring schema (http://www.asbmt.org). Acute leukemia in ﬁrst or second
complete remission, chronic myeloid leukemia in ﬁrst chronic phase,
Hodgkin or non-Hodgkin lymphoma in complete or partial chemotherapy
sensitive remission, chronic lymphocytic leukemia in ﬁrst remission, mye-
lodysplastic syndrome, or myeloproliferative disorder without excess blasts
were considered standard risk. All others were determined to be high risk at
the time of transplantation. Patient comorbidities at the time of HCT were
scored uniformly according to the hematopoietic cell transplantation
comorbidity index (HCT-CI) [26]. For categorical factors, P values were
Table 2
Baseline Bone and Endocrine Parameters
Factor Zoledronic Acid Standard of Care P Value
Measurement of effects
Baseline
Creatinine .88 (.54 to 1.97) .80 (.45 to 1.24) .45
Femoral neck (left) Z-score .65 (1.6 to 0.9) .8 (1.6 to 0.9) .44
Lumbar spine T-score .7 (2.5 to 2.3) .7 (2.1 to 1.9) .92
Lumbar spine Z-score .55 (3.3 to 2.1) .7 (2.1 to 1.9) .53
Femoral neck (right) Z-score .9 (1.7 to 1.4) .7 (91.5 to 1.0) .95
Femoral neck (right) T-score 1.2 (2.3 to 1.9) 1.15 (2.0 to .3) .81
Femoral neck (left) T-score 1.2 (2.2 to 1.4) 1.2 (2.3 to .1) .67
Calcium 9.15 (8.2 to 9.9) 9.2 (.6 to 9.9) .92
Femoral neck (left) BMD .9 (.74 to 1.25) .91 (.74 to 1.0) .83
Lumbar spine BMD 1.17 (.95 to 1.50) 1.11 (.94 to 1.42) .70
Femoral neck (right) BMD .90 (.75 to 1.32) .89 (.79 to 1.03) .63
Urinary N-terminal tel. 57.5 (18 to 438) 58 (19 to 961) .68
Ultrasensitive estradiol 15 (2.3 to 124) 11.5 (2.6 to 76) .38
LH 10.5 (2 to 46.7) 9.1 (.5 to 47.5) .56
FSH 14 (3.3 to 95.2) 22 (3.1 to 142) .43
TSH 1.7 (.1 to 5.2) 1.7 (.07 to 7.1) .69
FT4 1.0 (.7 to 3.4) 1.1 (.8 to 9.1) .46
Total testosterone 298 (1 to 656) 200 (2 to 1273) .84
Serum osteocalcin 22.8 (9 to 43) 21.5 (3.9 to 81) .68
Serum BSAP 13.6 (6.3 to 38.8) 12.7 (4.6 to 75.3) .73
BSAP indicates bone-speciﬁc alkaline phosphatase; BMD, bone mineral density; tel, telopeptide; FT4, free T4; LH, luteinizing hormone; FSH, follicle stimulating
hormone; TSH, thyroid stimulating hormone.
Data are presented as mean (range) unless otherwise indicated.
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cell counts. For continuous measures, P values were calculated by the
general Wilcoxon test. Comparison of the continuous primary and
secondary outcomes, which included measurements of the effect from
baseline to 3, 6, and 12 months after transplantation by randomization arm,
were performed by the Wilcoxon test. In addition to comparison by the
randomization arm, the effects of other baseline factors were evaluated for
their association on the primary outcome. These factors included Karnofsky
score, disease risk, center, comorbidity score, gender, donor type, and
conditioning. The difference in Karnofsky score from baseline to 6 and 12
months was performed by theMcNemar test for paired data [27]. Estimation
of survival was calculated by Kaplan-Meier curves and comparison of the
randomization groups was completed by the log-rank test [28]. Cumulative
incidence was used to estimate relapse, treating nonrelapse death as
a competing risk [29]. The correlation between the change in the femur and
the change in lumbar spine was measured by Spearman’s correlation coef-
ﬁcient. Conﬁdence limits were calculated using Fisher’s z transformation. All
P values were 2 sided. Analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC) and R 2.4 statistical software (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
Subject, Disease, and Transplantation Characteristics
The baseline characteristics of study subjects are
summarized in Table 1. Among the 64 subjects who signed
consent, 61 proceeded to randomization. Treatment and
control groups were similar regarding age, sex, weight,
indication for HCT, donor type, creatinine, conditioning
regimen intensity, GVHD prophylaxis, and year of HCT. The
proportion of subjects with high-risk disease was similar
across the 2 groups. However, the proportion of subjects in
the treatment group with comorbidities was signiﬁcantly
higher (P < .01) based upon HCT-CI scores. Of the treatment
and control groups, 50% and 21%, respectively, had HCT-CI
scores  3.
Bone mineral density, T-scores, Z-scores, UNTX, serum
osteocalcin, BSAP, thyroid function, LH, FSH, estradiol, and
testosterone levels between groups at baseline are summa-
rized in Table 2. Treatment and control groups were similar.
Baseline T-scores, Z-scores, and BMD at right and left femoral
neck and lumbar spine sites were also evenly distributed
between groups.Outcomes
The measurements of outcomes at 12 months after HCT
are summarized in Table 3. Thirty patients were evaluable for
outcomes (11 from the treatment group and 19 from the
control group); 31 patients were nonevaluable because of
early death, relapse, or withdrawal from study for compli-
cations or by choice. Serum creatinine, calcium levels, and
Karnofsky performance scores were similar between groups.
Subjects in the treatment arm had an improvement in
BMD at the femoral neck (mean change in BMD, .018
versus .054 for controls; P ¼ .04) and at the lumbar spine
(mean change in BMD, .048 versus .057 for controls; P <
.01). Statistically signiﬁcant improvements were observed for
the treatment group for T-score at the femoral neck (.20
versus .40; P ¼ .02) and lumbar spine (0.55 versus 0.45;
P < .01). Statistically signiﬁcant improvements were also
observed for the treatment group for Z score at the femoral
neck (0.30 versus 0.30; P ¼ .03). Evaluating changes in
BMD, T-scores, and Z-scores by patient and transplantation
characteristics showed no statistically signiﬁcant associa-
tions. The treatment group at 12 months had a signiﬁcant
decline in levels of the bone resorption marker UNTX (56
versus9 for control; P¼ .04) comparedwith baseline. There
were no signiﬁcant differences in other bone markers,
osteocalcin, and BSAP or endocrine markers (TSH, free T4,
FSH, LH, estradiol and testosterone). Spontaneous fractures
were observed in 1 patient in the control group. Changes in
femoral and lumbar spine BMD by treatment group are
represented in Figures 1 and 2. The correlation between the
BMD changes at the femoral neck and lumbar spine by
Spearman correlation coefﬁcient was .51 (95% conﬁdence
interval [CI], .17 to .73).
Mortality and toxicity during the study are summarized in
Tables 4 and 5, respectively. There was signiﬁcantly higher
mortality in the treatment group (15 deaths versus 6 deaths
within the ﬁrst year) resulting in a lower survival. Two-year
survival was signiﬁcantly lower at 43% (95% CI, 25% to 59%)
for the treatment group versus 75% (95% CI, 55% to 87%; P ¼
.006) for the control group. The incidences of relapse at 1 and
Table 3
Change in Measurements from Baseline to 12 Months
Factor Zoledronic Acid Standard of Care P Value
Baseline total 32 29
Evaluable at 12 mos 11 19
Creatinine change
Median (range) .24 (.10 to .71) .14 (.17 to .60) .32
Karnofsky score change
Median (range) 0 points (10 to 60) 0 points (10 to 20) .30
KPS increasing/unchanged 8 (73%) 15 (88%) .06
Serum osteocalcin 11 (31.2 to 3.7) 4.1 (35 to 67.4) .44
Serum BSAP 3 (14 to 4.6) 3 (14.4 to 5.2) .66
Urinary N-terminal tel. 56 (435 to 0) 9 (465 to 195) .04
Ultrasensitive estradiol 3.8 (2.3 to 45.7) 12.5 (3.9 to 69.1) .48
LH 1.0 (56 to 16.3) 3.0 (73 to 11) .91
FSH 5.8 (.6 to 17.7) 17.1 (133.4 to 91.3) .05
TSH .57 (1.41 to 5.56) .02 (2.77 to 4.55) .20
FT4 .14 (2.47 to .42) .02 (7.96 to .27) .16
Total testosterone 25 (284 to 278) 8.5 (395 to 99) .99
Lumbar spine
BMD .048 (.128 to .547) .057 (.215 to .093) <.01
T-Score .55 (.20 to 4.5) .45 (10.1 to .8) <.01
Z-Score .50 (.50 to 4.6) .20 (1.6 to 1.4) .06
Femoral neck (random)
BMD .018 (.204 to .126) .054 (.36 to .073) .04
T-Score .20 (1.5 to 1.0) .40 (2.6 to .50) .02
Z-Score .30 (1.6 to .9) .30 (2.7 to .60) .03
BSAP indicates bone-speciﬁc alkaline phosphatase; tel, telopeptide; FT4, free T4; LH, luteinizing hormone; FSH, follicle stimulating hormone; TSH, thyroid
stimulating hormone; BMD, bone mineral density.
Data are presented as mean (range) unless otherwise indicated.
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and chronic GVHD was similar. Primary causes of mortality
were similarly distributed between groups with relapse and
nonrelapse causes accounting for similar proportions in both
groups. Serious adverse events (> Common Toxicity Criteria
for Adverse Events (CTCAE) grade 3) included GVHD, infec-
tion, epistaxis, idiopathic pulmonary syndrome, and second
primarymalignancy. No cases of ONJ, renal failure, or other>
grade 3 adverse events attributable to ZA were observed.
DISCUSSION
There is considerable evidence of multifactorial bone loss
in HCT survivors. Most of the longitudinal studies in thisFigure 1. The 12-month change in bone mineral density (BMD) g/cm2 at thesetting have investigated bone loss during the ﬁrst year after
HCT and suggest that steep decline in BMD occurs in the
initial 6 to 12 months. Several prospective studies have
demonstrated that nonspeciﬁc interventions, such as
calcium, vitamin D supplementation, and sex hormone
replacement are inadequate preventive measures in the
setting of post-HCT bone loss [12,13,19]. The current study
was designed with the intent of reversing early bone loss
using the most potent bisphosphonate available, ie, ZA. We
are not aware of any other prospective, randomized data for
pre-emptive ZA use in the setting of osteopenia for early
post-alloHCT bone loss. The advantages of ZA are that of
rapid intravenous infusion, long duration of action, and highfemoral neck by treatment group (zoledronic acid [ZA] versus control).
Figure 2. The 12-month change in bone mineral density (BMD) g/cm2 at the lumbar spine by treatment group (zoledronic acid [ZA] versus control).
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dysfunction.
In this randomized study, we administered 3 doses of ZA
at 3-month intervals starting before HCT for recipients
identiﬁed to be at high risk of posttransplantation bone loss
by virtue of meeting criteria for osteopenia on pre-HCT DEXA
screening. The study therapy was successful in preventing
further bone loss and resulted in improvement in BMD and
T-scores at both the femoral neck and lumbar spine sites. The
bone resorption marker, UNTX, improved signiﬁcantly in the
treated group, suggesting a beneﬁt from ZA administration.
No fractures were observed in the study group, but the study
was not sufﬁciently powered or of sufﬁcient duration to
evaluate fracture risk. ZA was well tolerated and not associ-
ated with any cases of ONJ, renal impairment, or other
serious adverse events. Notably, although the study did not
complete expected accrual, the primary outcome showed
a statistically signiﬁcant advantage in favor of ZA. Among our
study population, we assessed the risk from various patientTable 4
Major Events by Randomization Arm
Factor Zoledronic Acid Standard of Care P Value
No. of patients 32 29
1-yr survival (95% CI) 47% (29% to 63%) 86% (67% to 95%) .002
2-yr survival (95% CI) 43% (25% to 59%) 75% (55% to 87%) .006
Primary cause of death
Relapse 11 (61%) 5 (71%)
Infection 3 (18%) 0
CMV pneumonia 1 (6%) 0
Pulmonary 1 (6%) 1 (14%)
GVHD 1 (6%) 1 (14%)
Other organ failure 1 (6%) 0
Spontaneous fractures 0 1
Osteonecrosis of jaw 0 0
Acute GVHD, highest grade
2 7 (22%) 4 (14%)
3 or 4 6 (19%) 2 (7%)
Chronic GVHD 6 (19%) 8 (28%)
Relapse
2 yrs 34% (17% to 41%) 30% (13% to 47%) .42
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus.
Data are presented as n (%) unless otherwise indicated.and transplantation-related factors on BMD: Karnofsky score
at baseline (<90 versus 90), disease risk (standard versus
high), center (Wisconsin versus Minnesota), comorbidity
score (HCT-CI) (low versus intermediate versus high), gender
(male versus female), donor type (sibling versus unrelated
donor versus umbilical cord blood), and conditioning (mye-
loablative versus nonmyeloablative). None of these factors
showed a statistically signiﬁcant association with bone loss.
There are considerable advantages to using ZA in the
prevention of post-HCT bone mineral loss [20]. Lower-
potency oral bisphosphonates, such as risedronate, have
shown limited beneﬁt in the prevention of post-HCT bone
loss. Also, oral low-potency agents need to be administered
on a chronic basis and are especially difﬁcult to deliver in the
early post-HCT period, when maximum bone loss occurs but
enteral alimentation may be relatively difﬁcult. Kananen
et al. randomized alloHCT recipients to 6 infusions of
pamidronate (60 mg, starting before HCT and continuing for
9 months) versus standard of care, which only involved
calcium, vitamin D, and sex hormone replacement in both
groups [19]. At 12 months after HCT, it appeared that
pamidronate prevented bone loss at the lumbar spine but
only reduced the degree of bone loss at other sites including
femoral neck. Very similar results were obtained in another
randomized study where monthly infusions of pamidronateTable 5
Serious Adverse Events
Factor Randomization Arm
Zoledronic
Acid
Standard
of Care
Total
No. of patients 32 29 61
Pneumonia, grade 5 2 0 2
New malignancy, grade 5 1 0 1
Pseudomonas sepsis, grade 5 1 0 1
GVHD, grade 3 or 4 2 0 1
Pulmonary syndrome, grade 5 0 1 1
Epistaxis (severe) 0 1 1
Deaths in ﬁrst year, grade 5 15 6 21
Total 21 8 29
GVHD indicates graft-versus-host disease.
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able to prevent bone loss at the lumbar spine [17]. The effects
appeared to be short lived and the authors recommended
trials using higher-potency bisphosphonates. The beneﬁts of
pamidronate have also been observed in children by
Carpenter et al. in a retrospective study [30]. In a 4-arm
study, Tauchmanova et al. compared calcium and vitamin D
supplementation alone versus the same treatment in
combination with hormone replacement versus oral weekly
risedronate for a year versus 3 monthly infusions of ZA [13].
At 12 months, compared to the nonbisphosphonate controls,
ZA increased lumbar and femoral BMD, whereas the beneﬁts
of risedronate were limited to lumbar BMD.
Tauchmanova et al., in another prospective study,
demonstrated that 3 monthly doses of ZA were able to
reverse bone loss and improve lumbar spine and femoral
neck BMD in alloHCT recipients with late accelerated bone
loss [14]. In contrast to our study, serial DEXA scans per-
formed after HCT (at a median of 12.2 months and
24.7 months) were used to identify rapid bone loss. Treat-
ment was delivered later than 12 months after HCT and
patients started at variable intervals. This strategy, although
feasible, does not address the rapid bone loss that occurs
maximally in the ﬁrst year after HCT. In a more recent study,
Ganguly et al. demonstrated that prophylactic ZA given
before the conditioning regimen and at 6 months after
alloHCT resulted in no change in DEXA scores; however, the
baseline BMD was within normal limits in 76% of their
patients [31]. We chose to use a pretransplantation DEXA
scan to screen for osteopenic recipients who would maxi-
mally beneﬁt from the intervention early after HCT. It may be
especially important to limit early bone loss after HCT, as
several studies have reported a persistent reduction in the
number and function of osteoblastic precursors within the
bone marrow after HCT [32-34]. The slow and inadequate
recovery of BMD after HCT may in part be caused by an
inability to regenerate a normal osteogenic cell compart-
ment. This may explain the lack of efﬁcacy of nonspeciﬁc
strategies aimed at improving bone density and suggests that
the prevention of early post-HCT bone loss maybe the most
important prophylactic strategy.
Unexpectedly, we observed lower 1- and 2-year survivals
in the treatment group, primarily related to higher overall
mortality in the treatment group. Serious adverse events
related to bisphosphonates appeared to not be the reason for
the higher mortality. Although the ZA group and controls
were well matched in most patient, disease, and HCT-related
variables, there was considerable baseline disparity in pre-
transplantation comorbidity scores. In the ZA treatment
group, 50% had high-risk comorbidity scores (HCT-CI  3)
compared with 21% in the control group. This disparity likely
explains the overall higher mortality in this group. Relapse
rates were similar across both groups and the proportion of
deaths attributable to relapse and nonrelapse mortality were
also similar. This suggests the effect of an overall prognostic
factor, such as comorbidity, driving higher mortality in the
ZA group. HCT-CI scores have been implicated and validated
in multiple studies as an independent predictor of mortality
after HCT [35,36]. The study intervention is highly unlikely,
in our opinion, to have played a role in survival outcomes.
In summary,wewere able to demonstrate, in a randomized
fashion, that early pre-emptive intervention with ZA is effec-
tive in preventing post-HCT bone mineral loss in at-risk adult
alloHCTrecipients,with acceptable toxicity. Further studies are
needed to conﬁrm this ﬁnding in a larger patient population.ACKNOWLEDGMENTS
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